MYOMO, INC. 8-K

What Happened

• Myomo, Inc. filed an 8-K (April 16, 2026) reporting that the Board appointed William J. Febbo as a Class II director effective April 14, 2026. He will serve until his term expires at the 2028 annual meeting of shareholders. The company also announced compensation arrangements including equity and cash for his non-employee director role. A press release was furnished as Exhibit 99.1.

Key Details

• Appointment date: April 14, 2026; director term ends at the 2028 annual meeting.
• Equity grant: 45,000 restricted stock units (RSUs) granted on appointment, which vest in full on the one-year anniversary of his appointment.
• Annual compensation: $60,000 cash retainer plus $85,000 in RSUs annually (the RSUs vest over four quarterly installments).
• Background: Febbo (age 57) is CEO and Director of Performance Health Systems (joined Feb 2026); previously CEO of OptimizeRx Corporation (2015–2024). No related-party transactions requiring disclosure; he entered the company’s standard indemnification agreement. He was not assigned to any Board committees at appointment.

Why It Matters

• Board composition and director experience can affect governance and strategic oversight. Febbo’s healthcare and health-technology executive background and recent CEO roles may align with Myomo’s focus on mobility and assistive devices. The disclosed equity and cash awards are material to shareholder dilution and director compensation trends. Investors should note the term length (through 2028) and the vesting schedules for the RSUs when evaluating potential impacts on outstanding shares and corporate governance.